Savara
SVRA
Market cap $549M

3.20 USD

-0.05

1.54%

At close Dec 24, 4:00 PM EST

After hours

3.09

-0.11

3.44%

1 day

-1.54%

5 days

-1.23%

1 month

-6.16%

3 months

-27.60%

6 months

-12.57%

Year to date

-26.77%

1 year

-33.05%

5 years

79.78%

10 years

-63.47%

About: Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Employees: 37

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

255% more call options, than puts

Call options by funds: $501K | Put options by funds: $141K

115% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 26

10% more capital invested

Capital invested by funds: $619M [Q2] → $680M (+$61.3M) [Q3]

5% less funds holding

Funds holding: 131 [Q2] → 125 (-6) [Q3]

13.65% less ownership

Funds ownership: 111.16% [Q2] → 97.51% (-13.65%) [Q3]

24% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 25

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$5

56%

upside

Avg. target

$7

119%

upside

High target

$9

181%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

Wells Fargo Tiago Fauth 70% 1-year accuracy 14 / 20 met price target	150%upside $8	Overweight Initiated	20 Dec 2024
JMP Securities Jonathan Wolleben 47% 1-year accuracy 35 / 75 met price target	181%upside $9	Market Outperform Reiterated	19 Dec 2024
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 102 / 328 met price target	88%upside $6	Buy Maintained	13 Nov 2024
Evercore ISI Group Liisa Bayko 45% 1-year accuracy 5 / 11 met price target	56%upside $5	In-Line Downgraded	13 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about SVRA published over the past 30 days

Savara Announces New Employment Inducement Grant

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On December 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 100,000 shares of the Company's common stock and rest.

Savara Announces New Employment Inducement Grant

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. MOLBREEVI was granted Fast Track and Breakthrough Therapy Designations in 2019 for the treatment of patients with.

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference. Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ET Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara Location: Westin St. Francis, San Francisco, Elizabethan C Room The live webcast and subsequent r.

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Savara Announces New Employment Inducement Grant

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On November 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 80,000 shares of the Company's common stock and restr.

Savara Announces New Employment Inducement Grant

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society (BTS) Winter Meeting, taking place November 27-29, 2024, in London, England. BTS Platform Presentation Details Title: “Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Re.

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Savara Announces Participation in Upcoming Healthcare Conferences

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats. Jefferies London Healthcare Conference, November 19-21, 2024 Fireside Chat: November 20th, 1:00pm GT/8:00am ET/5:00am PT Piper Sandler 36th Annual Healthcare Conference, December 3-5, 202.

Savara Announces Participation in Upcoming Healthcare Conferences

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024 and provided a business update. “After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potentia.

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 12, 2024 at 10:00am PT/1:00pm ET. A live webcast and subsequent replay of the fireside chat will be available on Savara's website at https://savarapharma.com/investors/events-presentations/ and will be ar.

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that a new episode of The Balancing Act®, sponsored by Savara and featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP), is airing on Lifetime TV's Behind the Mystery™ a recurring series on The Balancing Act® television show devoted to advocating for people with rare and genetic diseases. The episode centers on the diagnostic.

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

Savara Announces New Employment Inducement Grant

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On October 17, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 95,000 shares of the Company's common stock and restri.

Savara Announces New Employment Inducement Grant

See News Rankings

Charts implemented using Lightweight Charts™